Chemomab Therapeutics Ltd.: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on May 12, 2022 and accepted by EDGAR at May 12, 2022, 08:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-01-01 to 2022-03-31 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months2022-01-01 to 2022-03-31 | −$5.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | −$3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-03-31 | $14.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-03-31 | $13.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $59.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $61.0m | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $3.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-03-31 | $3.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-03-31 | $57.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001178913-22-001919. Last ingested by Listed: Nov 3, 2026, 08:33 ET. Listed shows no prices and gives no investment advice.